Pfizer (PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision allosteric therapeutics. Read more here.

This partnership could redefine precision medicine with groundbreaking therapeutics targeting "impossible" proteins.

Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik ...

Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to ...

Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its ...

Atavistik Bio enters research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics: Cambridge, Massachusetts Friday, January 3, 2025, 15:00 ...

(RTTNews) - Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to accelerate the discovery of novel precision ...

Collaboration will leverage Atavistik Bio's proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has ...